170 related articles for article (PubMed ID: 9726699)
1. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
[TBL] [Abstract][Full Text] [Related]
2. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
3. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
5. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin.
Antila S; Jarvinen A; Honkanen T; Lehtonen L
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):705-10. PubMed ID: 11214780
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
[TBL] [Abstract][Full Text] [Related]
9. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol.
Antila S; Järvinen A; Akkila J; Honkanen T; Karlsson M; Lehtonen L
Arzneimittelforschung; 1997 Jul; 47(7):816-20. PubMed ID: 9272237
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
[TBL] [Abstract][Full Text] [Related]
11. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
Sundberg S; Lehtonen L
Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole increases plasma concentrations of quinidine.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan.
Figgitt DP; Gillies PS; Goa KL
Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
[TBL] [Abstract][Full Text] [Related]
14. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
15. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
16. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
Põder P; Eha J; Antila S; Heinpalu M; Planken U; Loogna I; Mesikepp A; Akkila J; Lehtonen L
Cardiovasc Drugs Ther; 2003; 17(5-6):451-8. PubMed ID: 15107600
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
